Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

The interchangeable Semglee product, which will allow substitution of Semglee for the reference product, Lantus(R), at the pharmacy counter, will be introduced before the end of the year.